Malaria And Sickle Cell Disease Treatment Market Scope And Analysis

  • Report Code : TIPRE00030125
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 420
Buy Now

Malaria and Sickle Cell Disease Treatment Market Scope and Key Players Analysis by 2030

Buy Now

Malaria and Sickle Cell Disease Treatment Market Report Malaria and Sickle Cell Disease Treatment Market Size and Share Malaria and Sickle Cell Disease Treatment Market Scope and Analysis

Malaria and Sickle Cell Disease Treatment Market Report Scope

Report Attribute Details
Market size in 2022 US$ 4.46 Billion
Market Size by 2030 US$ 29.18 Billion
Global CAGR (2022 - 2030) 26.5%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By Treatment
  • Malaria
  • Sickle Cell Disease
By Route of Administration
  • Oral and Parenteral
By Distribution Channel
  • Direct Tender
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Cipla Ltd
  • Pfizer Inc
  • Sun Pharmaceutical Industries Ltd
  • Sanofi SA
  • GSK Plc
  • Novartis AG
  • Pfizer Inc
  • Emmaus Life Sciences Inc
  • AdvaCare Pharma USA LLC

    • Industry Developments and Future Opportunities: 

    Various initiatives taken by key players operating in the global malaria and sickle cell disease treatment market are listed below:

    1. In November 2022, Novartis and Medicines for Malaria Venture (MMV) announced decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated malaria. This novel combination also contains an optimized formulation of lumefantrine, which allows it to be given once daily versus the usual twice-daily administration.
    2. In October 2022, Pfizer Inc acquired Global Blood Therapeutics Inc. GBT brings a portfolio and pipeline that has the potential to address the full spectrum of critical needs for this underserved community. GBT discovered and developed Oxbryta (voxelotor), a first-in-class medicine that directly targets the root cause of SCD.

    Competitive Landscape and Key Companies:

    Cipla Ltd, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, Emmaus Life Sciences Inc, AdvaCare Pharma USA LLC, VLP Therapeutics LLC, and Lupin Ltd are among the major malaria and sickle cell disease treatment companies. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.